Delivery Order SPE2DR25D2014-SPE2DR26FZ61B
- Not listed
- The Defense Logistics Agency awarded a $8,170 firm fixed-price delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on April 21, 2025, with an ultimate completion date of April 22, 2025. This non-competitive delivery order was placed against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The pharmaceutical product will be performed at the contractor's Conshohocken,...
- The Defense Logistics Agency awarded a $17,422.25 delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL, a pharmaceutical product used in treating inflammatory conditions. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of September 4, 2025, and performance occurring at AmerisourceBergen's Conshohocken, Pennsylvania location. The delivery order is issued under a larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $4,531.80 to AmerisourceBergen Drug Corp for HUMIRA Pen 40 mg/0.8 mls on November 3, 2025, with an ultimate completion date of November 4, 2025. This contract is structured as a firm fixed price delivery order with no set-aside designation, indicating it was awarded competitively. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,207.72 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on November 3, 2025, with an ultimate completion date of November 4, 2025. This is a firm fixed price, competitively awarded delivery order with no set-aside designation, issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion through December 2026. The place of...
- The Defense Logistics Agency awarded a $4,531.80 firm fixed-price delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls, a injectable pharmaceutical product used in treating autoimmune conditions. The award, issued on October 28, 2025, with an ultimate completion date of October 29, 2025, represents a non-set-aside competitive procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this...
- The Defense Logistics Agency awarded a delivery order valued at $4,741.71 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL pharmaceutical supplies. The contract is a firm fixed price delivery order with an ultimate completion date of July 28, 2025, and represents a non-set-aside competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $1,510.60 firm fixed-price delivery order to AmerisourceBergen Drug Corp for HUMIRA Pen 40 mg/0.8 mL pharmaceutical supplies on September 3, 2025, with completion targeted for September 4, 2025. This non-competitive delivery order is being fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a $2,265.90 firm fixed-price delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on August 28, 2025, with an ultimate completion date of August 29, 2025. This non-set-aside contract represents a pharmaceutical supply delivery under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The delivery location is...
- The Defense Logistics Agency awarded a $4,849.35 firm fixed-price delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls pharmaceutical supply, with an ultimate completion date of August 12, 2025. This non-set-aside competitive award was issued on August 11, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 3, 2025, for the supply of HUMIRA Pen 40 mg/0.8 mls, a biologic medication used to treat inflammatory conditions. This firm fixed-price delivery order, valued at $1,575.72, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion prime vendor agreement running through December 2026. The award was made on a...
- SPE2DR25D2014Indefinite Delivery Contract
- SPE2DR25D2014-SPE2DR26FZ61BDelivery Order
The Defense Logistics Agency awarded a $4,775.88 firm fixed-price delivery order to AmerisourceBergen Drug Corp on November 3, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL, with an ultimate completion date of November 4, 2025. This non-set-aside competitive award was issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive $999,999,999.00 global pharmaceutical support vehicle valued through December 2026. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical federal vendor for military and veteran healthcare systems through its extensive federal contract portfolio. The parent IDC with DLA enables the company to supply a diverse range of pharmaceutical products, medical devices, vaccines, and specialized healthcare commodities across multiple therapeutic domains to support Defense Health Agency and other government healthcare systems worldwide. This specific delivery order represents a routine fulfillment under the broader pharmaceutical prime vendor arrangement, delivering a branded injectable treatment for patients within the military healthcare system.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.8k | 11/3/25 |